(redirected from Benign prostatic hypertrophy)
Also found in: Dictionary, Thesaurus, Medical, Acronyms.


(hīpûr`trəfē), enlargement of a tissue or organ of the body resulting from an increase in the size of its cells. Such growth accompanies an increase in the functioning of the tissue. In normal physiology the growth in size of muscles (e.g., in an athlete as a result of increased exercise) and also the enlargement of a uterus in pregnancy are caused by hypertrophy of muscle cells. In pathology the thickening of the heart muscle from overstrain, as in hypertensionhypertension
or high blood pressure,
elevated blood pressure resulting from an increase in the amount of blood pumped by the heart or from increased resistance to the flow of blood through the small arterial blood vessels (arterioles).
..... Click the link for more information.
 (high blood pressure), is the result of hypertrophy. An organ subjected to extra work (e.g., the one kidney left to function after surgical removal of the other) usually compensates by enlarging; in such cases hyperplasia, an increase in the number of cells, generally accompanies hypertrophy.



an increase in the volume of a body organ or of any of its parts.

Hypertrophy in man (or in animals) may occur either as the result of the enlargement of the individual component elements of an organ (cells and tissues) or as the result of an increase in their quantity (hyperplasia). True hypertrophy and false hypertrophy are distinguished. The former includes enlargement in volume or mass of specific elements as the result of an increased functional load (so-called functional, or compensatory, hypertrophy) or disruption of the regulatory influences of the nervous and endocrine systems. Functional hypertrophy may appear in healthy persons who are occupied with physical labor, such as in athletes (“physiologic hypertrophy” of the muscles). It may also appear upon affection of a part of any organ, such as after heart failure (compensatory hypertrophy) or after the destruction of a paired organ, such as a kidney (vicarious hypertrophy). Compensation for the impaired functions occurs in all instances of functional hypertrophy. Examples of hypertrophy occurring as a result of the disruption of neuroendocrine influences include acromegaly and gynecomastia; in these cases the hypertrophy has no compensatory significance but is accompanied by considerable disturbances of function. False hypertrophy refers to enlargement of the organ as the result of excessive growth of the interstitial, most often the adipose, tissue in response to atrophy of the parenchyma (the functional tissue). Function of the organ in such cases is usually decreased.


Hypertrophy of plant organs is the result of an increase in the size of their cells. The hypertrophy may be the effect of increased synthesis of the substances of the cell membrane or cytoplasm, deposits of reserve compounds, or the development of polynucleosis or polyploidy. The causes of hypertrophy include disruption of the synthesis and metabolism of phenol compounds, amino acids, proteins, carbohydrates, and fats, as well as deficiency of trace elements. The condition may also be caused by viruses, bacteria, fungi, invertebrates, and plant parasites. It may accompany many mutations, grafts, and the effects on the plant of ionizing radiation or ultrasound. Hypertrophy is usually interconnected with hyperplasia and disruptions of tissue differentiation in the organs. In many instances (for example, when there is development of tumors or galls) hypertrophy follows cell division; after mechanical injury and physical or chemical effects, however, it is often primary. Hypertrophy is observed in higher as well as in lower plants.



Increase in cell size causing an increase in the size of an organ or tissue.


enlargement of an organ or part resulting from an increase in the size of the cells
References in periodicals archive ?
In March of this year Synaptic began to make available non-exclusive licenses to its alpha adrenergic and benign prostatic hypertrophy patents.
It should be stressed that residents with documentation of a spinal cord injury, benign prostatic hypertrophy, neurogenic bladder, an active urinary tract infection or Alzheimer's Disease are not good candidates for toileting schedules.
Clinical evaluation of cernilton in the treatment of the benign prostatic hypertrophy.
Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.
It's subject to false positives that can be very scary until further tests reveal that there's no cancer, just benign prostatic hypertrophy.
Men who take both types of anticholinergics concomitantly and men who have benign prostatic hypertrophy (BPH) are at highest risk for developing acute urinary retention, which is considered a urologic emergency, said Dr.
Blue nevus is the commonest melanocytic lesion arising in the prostate that is usually an incidental finding on transurethral resection for benign prostatic hypertrophy or at autopsy.
High-intensity focused ultrasound experimentation on human benign prostatic hypertrophy.
27 January 2010 - US biopharmaceutical company Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) said today it has decided to discontinue the development of ozarelix in benign prostatic hypertrophy (BPH).
Low blood pressure also can be caused by medications (even those not given for the purpose of lowering blood pressure) including those taken to treat benign prostatic hypertrophy, other cardiac conditions, and Parkinson's disease.
Benign Prostatic Hypertrophy (BPH), or enlargement of the prostate, is caused by an over-production of the growth-stimulating hormone DHT, which is found in testosterone.

Full browser ?